Sepsis, a leading cause of global mortality, requires prompt and accurate antibiotic administration. Proper dosing ensures therapeutic success while reducing the likelihood of adverse effects. Despite this, standardized treatment approaches frequently disregard sex and gender differences that shape pharmacological responses. This editorial article underscores the significance of these variables and advocates revising clinical guidelines to integrate sex- and gender-specific considerations into antimicrobial therapy and decision-making.

Researchers at Washington University School of Medicine in St. Louis have identified central routes that two deadly viruses take to invade human cells and have designed decoy molecules that block the infections. The discoveries — published this week in two separate studies — set the stage for developing new prevention and treatment strategies for yellow fever virus and tick-borne encephalitis viruses.

New research shows that eosinophils, immune cells usually linked to allergies, also play a protective role against Candida infections by using the CD48 receptor to recognize the fungus and release proteins that stop its growth. This discovery is important because it reshapes how we understand the immune system and opens the door to new therapies that could strengthen natural defenses against life-threatening fungal infections, a growing challenge in hospitals worldwide.